Claims
- 1. A compound of the formula: ##STR40## wherein R represents alkyl having 2 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, or --(CH.sub.2).sub.m --R.sup.3 wherein R.sup.3 represents cycloalkyl of 3 to 5 carbons atoms and m is 1 or 2;
- R.sup.1 represents alkyl having 1 to 4 carbon atoms;
- R.sup.2 represents hydrogen or alkyl having 1 to 5 carbon atoms;
- R.sup.4 represents alkyl having 1 to 6 carbon atoms;
- n is an integer from 1 to 5;
- p is an integer from 0 to 6;
- Y represents oxygen; and
- Z represents hydrogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 are independently hydrogen or alkyl having 1 to 4 carbon atoms, or SR.sup.6 wherein R.sup.6 is, hydrogen, benzyl or alkyl having 1 to 4 carbon atoms;
- and the stereoisomers and pharmaceutically acceptable salts thereof.
- 2. A compound according to claim 1 of the formula ##STR41## wherein R represents alkyl having 2 to 4 carbon atoms, alkenyl having 3 to 4 carbon atoms, or cyclopropylalkyl wherein the alkyl moiety has 1 to 2 carbon atoms;
- R.sup.1 represents methyl or ethyl;
- R.sup.2 represents hydrogen or alkyl having 1 to 3 carbon atoms;
- n is an integer from 1 to 3;
- p is an integer from 0 to 4;
- Y represents oxygen; and
- Z represents hydrogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, NH.sub.2 or SR.sup.6 wherein R.sup.6 is, hydrogen benzyl, or alkyl having 1 to 4 carbon atoms; and the stereoisomers and pharmaceutically acceptable salts thereof.
- 3. A compound according to claim 1 of the formula ##STR42## wherein R represents propyl, 2-propenyl, or cyclopropylmethyl;
- p is an integer from 0 to 2;
- Y represents oxygen; and
- Z represents hydrogen, NH.sub.2, alkyl having 1 to 2 carbon atoms, alkoxy having 1 to 2 carbon atoms, or SR.sup.6 wherein R.sup.6 is hydrogen, benzyl or methyl; and the stereoisomers and pharmaceutically acceptable salts thereof.
- 4. A compound according to claim 3 which is 3,4-dihydro-7-[3-[3-methoxy-4-(4-oxazolyl)-2-propylphenoxylpropoxyl-8-propyl-2H-1-benzopyran-2-carboxylic acid.
- 5. A compound according to claim 3 which is 3,4-dihydro-7-[3-[3-methoxy-4-(2-methyl-4-oxazolyl)-2-propylphenoxy]propoxy]-8-propyl-2H-1-benzopyran-2-carboxylic acid.
- 6. A pharmaceutical composition for treating leukotriene B.sub.4 mediated conditions comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 7. A pharmaceutical composition for treating leukotriene B.sub.4 mediated inflammatory diseases comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 8. A pharmaceutical composition according to claim 7 for treating inflammatory diseases comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.
- 9. A pharmaceutical composition according to claim 7 for treating inflammatory diseases comprising a therapeutically effective amount of a compound of claim 3 and a pharmaceutically acceptable carrier.
- 10. A pharmaceutical composition according to claim 7 for treating inflammatory diseases comprising a therapeutically effective amount of a compound of claim 4 and a pharmaceutically acceptable carrier.
- 11. A method of treating leukotriene B.sub.4 mediated conditions comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 12. A method of treating leukotriene B.sub.4 mediated inflammatory diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 13. A method according to claim 12 of treating inflammatory diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.
- 14. A method according to claim 12 of treating inflammatory diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 3.
- 15. A method according to claim 12 of treating inflammatory diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 4.
- 16. A method according to claim 12 wherein the inflammatory disease is rheumatoid arthritis.
- 17. A method according to claim 12 wherein the inflammatory disease is psoriasis.
- 18. A method according to claim 12 wherein the inflammatory disease is inflammatory bowel disease.
- 19. A method according to claim 12 wherein the inflammatory disease is gout.
- 20. A method according to claim 12 wherein the inflammatory disease is asthma.
- 21. A method according to claim 12 wherein the inflammatory disease is multiple sclerosis.
Parent Case Info
This is a division, of application Ser. No. 07/521,777, filed May 10, 1990 now U.S. Pat. No. 5,073,562.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
3882148 |
Augstein et al. |
May 1975 |
|
4281008 |
Chamberlain et al. |
Jul 1981 |
|
4546194 |
Miyano et al. |
Oct 1985 |
|
4565882 |
Miyano et al. |
Jan 1986 |
|
4665203 |
Miyano et al. |
May 1987 |
|
4889871 |
Djuric et al. |
Dec 1989 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
0017332 |
Feb 1980 |
EPX |
0150447 |
Dec 1984 |
EPX |
0129906 |
Jan 1985 |
EPX |
0079637 |
Jan 1987 |
EPX |
Non-Patent Literature Citations (2)
Entry |
R. A. Appleton et al. Antagonists of Slow Reacting Substance of etc. J. Med. Chem. 20(3) 371-379 Jan. 1977. |
Chemical Abstracts Benzopyran antimetabolites 103:160389g 103(19) 699 Nov. 1985. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
521777 |
May 1990 |
|